Business Wire

SCORO

9.3.2021 11:02:10 CET | Business Wire | Press release

Share
Scoro Raises $16 Million in Series B Funding To Invest In Its End-to-End Work Management Software

Scoro , an award-winning work management software for professional service businesses, has closed a $16.4 million Series B funding round led by Kennet Partners. Additional investors include Columbia Lake Partners, Inventure, Livonia Partners and Tera Ventures. The investment will fuel continued global expansion and is supported by new French and Spanish versions of the software.

“Even before Covid-19 hit, most professional service businesses used as many as a dozen different platforms daily,” said Scoro’s Founder and CEO, Fred Krieger . “However, teams now realise that constantly switching between tools harms productivity and results in lost data and duplicated work. In many ways, these tools became weapons of mass distraction. We’re proud to have the support of Kennet Partners and other investors as we help businesses identify and remove these weapons of mass distraction with our end-to-end work management software.”

Scoro's most recent product launch has been a modernization of the Gantt chart , which had not evolved since its creation at the turn of the 19th Century. With the new funding, Scoro will continue to create innovative tools which enable professional service businesses to improve their productivity and profitability.

“The dramatic disruption to working practices caused by Covid-19 should give us pause for thought, challenge our assumptions, and encourage us to think about what the new normal should be,” said Dave Kellogg , a highly experienced SaaS advisor and new addition to Scoro’s Board of Directors. “The evolution of the workplace will be supported by platforms such as Scoro which enable staff to communicate and collaborate effectively, flexibly and without distraction.”

Kennet Partners’ Managing Director Hillel Zidel also joins the Board of Directors, alongside Dave Kellogg. Martin Fincham continues to lead the Board of Directors as Scoro’s Chairman.

“It is a privilege to chair such a high calibre Board and very reassuring to be supported on our scale-up journey by some of Europe’s top B2B SaaS investors,” added Martin Fincham.

“Scoro is a great example of the type of high-growth, founder-led B2B SaaS company we love to invest in at Kennet,” said Hillel Zidel. “Clients get a lot of value out of Scoro and I’m very excited to support the company in its international expansion at a time when so many businesses are looking for productivity gains.”

Scoro now joins an elite group of start-ups founded in Estonia that have raised more than $20 million in venture capital. Estonia is the world leader in creating technology unicorns per capita, with successes including Skype, Transferwise, Bolt and Pipedrive.

To learn more about Scoro’s end-to-end work management software and how it helps professional service businesses boost productivity and profitability, visit www.scoro.com .

##### ENDS #####

About Scoro

Scoro is an award-winning work management software platform for collaborative teams in the professional services and creative industries.

Thousands of teams in more than 60 countries trust Scoro to increase their margins, save them time and accelerate data-driven decision making. Unlike traditional single-use solutions, Scoro is scalable across an entire business – from projects and sales through to billing and reporting.

Founded in 2013 by Fred Krieger, Scoro is headquartered in London, with additional offices in Tallinn and New York. Scoro has been listed in Deloitte’s Technology Fast 50 list and the Inc. 5000 list. For more information, visit www.scoro.com .

About Kennet Partners
Kennet is a leading international growth equity firm that invests in high-growth companies in Europe and North America. With offices in London and Silicon Valley, the firm supports entrepreneurial technology businesses with expansion capital to accelerate growth and build exceptional shareholder value. Kennet is an experienced investor with approximately $900 million in funds under management. For more information, visit www.kennet.com .

About Columbia Lake Partners
Columbia Lake Partners is an experienced team of investors providing investment for growing technology companies across Europe. Columbia Lake Partners’ portfolio has extended investment of more than €300 million to over 100 companies. For more information, visit www.clpgrowth.com .

About Inventure
Inventure is one of the most experienced Nordic venture funds that specializes in helping its portfolio companies with talent and expansion. Since 2005, the team has been in venture with over 70 companies ranging from deep tech to consumer internet brands, including Wolt, Detectify, Blueprint Genetics, and Swappie. For more information, visit www.inventure.vc .

About Livonia Partners
Livonia Partners is a private equity and growth capital firm which invests in companies with a strong growth potential, providing investments in the range of €10 million to €20 million. For more information, visit www.livoniapartners.com .

About Tera Ventures
Founded in 2016, Tera Ventures is an international investment firm which enables disruptive technology companies to scale into global leaders. For more information, visit www.tera.vc .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye